{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:19:01Z","timestamp":1792592341789,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40264-025-01558-1","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T04:12:05Z","timestamp":1751256725000},"page":"1089-1101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association of GLP1-Receptor Agonists with Risk of Hepatocellular Carcinoma: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"48","author":[{"given":"Joane","family":"Titus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Katukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moheb","family":"Boktor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6122-3716","authenticated-orcid":false,"given":"Ishak A.","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"issue":"9","key":"1558_CR1","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","volume":"76","author":"SR Das","year":"2020","unstructured":"Das SR, Everett BM, Birtcher KK, et al. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(9):1117\u201345. https:\/\/doi.org\/10.1016\/j.jacc.2020.05.037.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1558_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/87551225241266773","volume":"40","author":"A Krishnan","year":"2024","unstructured":"Krishnan A, Suryanarayanan SK, Mansi IA. Utilization of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitors at the Veterans Health Administration. J Pharm Technol. 2024;40(5):223\u20139. https:\/\/doi.org\/10.1177\/87551225241266773.","journal-title":"J Pharm Technol"},{"issue":"3","key":"1558_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.mehy.2013.11.034","volume":"82","author":"Y Sun","year":"2014","unstructured":"Sun Y, Fan L, Meng J, Zhang F, Zhang D, Mei Q. Should GLP-1 receptor agonists be used with caution in high risk population for colorectal cancer? Med Hypotheses. 2014;82(3):255\u20136. https:\/\/doi.org\/10.1016\/j.mehy.2013.11.034.","journal-title":"Med Hypotheses"},{"issue":"3","key":"1558_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cmet.2015.02.005","volume":"21","author":"JA Koehler","year":"2015","unstructured":"Koehler JA, Baggio LL, Yusta B, et al. GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. Cell Metab. 2015;21(3):379\u201391. https:\/\/doi.org\/10.1016\/j.cmet.2015.02.005.","journal-title":"Cell Metab"},{"issue":"5","key":"1558_CR5","doi-asserted-by":"publisher","first-page":"F77","DOI":"10.1530\/erc-12-0111","volume":"19","author":"R Vangoitsenhoven","year":"2012","unstructured":"Vangoitsenhoven R, Mathieu C, Van der Schueren B. GLP1 and cancer: friend or foe? Endocr Relat Cancer. 2012;19(5):F77-88. https:\/\/doi.org\/10.1530\/erc-12-0111.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"1558_CR6","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc22-1148","volume":"46","author":"J Bezin","year":"2022","unstructured":"Bezin J, Gouverneur A, P\u00e9nichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2022;46(2):384\u201390. https:\/\/doi.org\/10.2337\/dc22-1148.","journal-title":"Diabetes Care"},{"issue":"2","key":"1558_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2337\/dci22-0052","volume":"46","author":"CA Thompson","year":"2023","unstructured":"Thompson CA, St\u00fcrmer T. Putting GLP-1 RAs and thyroid cancer in context: additional evidence and remaining doubts. Diabetes Care. 2023;46(2):249\u201351. https:\/\/doi.org\/10.2337\/dci22-0052.","journal-title":"Diabetes Care"},{"issue":"5","key":"1558_CR8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513\u20139. https:\/\/doi.org\/10.1001\/jamainternmed.2022.0338.","journal-title":"JAMA Intern Med"},{"key":"1558_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i5519","volume":"355","author":"SD Bolen","year":"2016","unstructured":"Bolen SD, Maruthur NM. Glucagon-like peptide-1 receptor agonists and risk of breast cancer. BMJ. 2016;355: i5519. https:\/\/doi.org\/10.1136\/bmj.i5519.","journal-title":"BMJ"},{"key":"1558_CR10","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1136\/bmj.i5340","volume":"355","author":"BM Hicks","year":"2016","unstructured":"Hicks BM, Yin H, Yu OH, Pollak MN, Platt RW, Azoulay L. Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink. BMJ. 2016;355:5340. https:\/\/doi.org\/10.1136\/bmj.i5340.","journal-title":"BMJ"},{"issue":"3\u20134","key":"1558_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/rds.2014.11.202","volume":"11","author":"TD Filippatos","year":"2014","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud Fall-Winter. 2014;11(3\u20134):202\u201330. https:\/\/doi.org\/10.1900\/rds.2014.11.202.","journal-title":"Rev Diabet Stud. Fall-Winter"},{"issue":"1","key":"1558_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/07435800.2021.1955255","volume":"47","author":"J Wang","year":"2022","unstructured":"Wang J, Kim CH. differential risk of cancer associated with glucagon-like peptide-1 receptor agonists: analysis of real-world databases. Endocr Res. 2022;47(1):18\u201325. https:\/\/doi.org\/10.1080\/07435800.2021.1955255.","journal-title":"Endocr Res"},{"issue":"7","key":"1558_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.21305","volume":"7","author":"L Wang","year":"2024","unstructured":"Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open. 2024;7(7): e2421305. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.21305.","journal-title":"JAMA Netw Open"},{"key":"1558_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107401","volume":"208","author":"G Figlioli","year":"2024","unstructured":"Figlioli G, Piovani D, Peppas S, et al. Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2024;208: 107401. https:\/\/doi.org\/10.1016\/j.phrs.2024.107401.","journal-title":"Pharmacol Res"},{"key":"1558_CR15","doi-asserted-by":"publisher","first-page":"1534365","DOI":"10.1155\/2019\/1534365","volume":"2019","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhang X, Chai S, Zhao X, Ji L. Risk of malignant neoplasia with glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes: a meta-analysis. J Diabetes Res. 2019;2019:1534365. https:\/\/doi.org\/10.1155\/2019\/1534365.","journal-title":"J Diabetes Res"},{"issue":"5","key":"1558_CR16","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/hep.23569","volume":"51","author":"NA Gupta","year":"2010","unstructured":"Gupta NA, Mells J, Dunham RM, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010;51(5):1584\u201392. https:\/\/doi.org\/10.1002\/hep.23569.","journal-title":"Hepatology"},{"issue":"12","key":"1558_CR17","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","volume":"3","author":"T Akinyemiju","year":"2017","unstructured":"Akinyemiju T, Abera S, Ahmed M, et al. The Burden of Primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3(12):1683\u201391. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3055.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1558_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1558_CR19","unstructured":"VA Informatics and Computing Infrastructure (VINCI), VA HSR RES 13-457, U.S. Department of Veterans Affairs. (2008). Retrieved [date], from https:\/\/vincicentral.vinci.med.va.gov."},{"key":"1558_CR20","unstructured":"National Healthcare Quality and Disparities Report: Chartbook on Healthcare for Veterans [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Nov. OVERVIEW OF VHA PATIENT, VETERAN, AND NON-VETERAN POPULATIONS AND CHARACTERISTICS. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK578553\/. Accessed 19 Mar 2025."},{"issue":"4","key":"1558_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund JL, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221\u20138. https:\/\/doi.org\/10.1007\/s40471-015-0053-5.","journal-title":"Curr Epidemiol Rep."},{"key":"1558_CR22","unstructured":"Elixhauser A, Steiner C, Palmer L. Clinical Classifications Software (CCS) for ICD-9-CM. Databases and Related Tools from the Healthcare Cost and Utilization Project (HCUP) U.S. Agency for Healthcare Research and Quality; 2012:Appendix A. Accessed 01\/01\/2012. http:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/ccs\/ccs.jsp. Accessed 16 Mar 2015."},{"issue":"1","key":"1558_CR23","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/hep.31726","volume":"74","author":"H Hagstr\u00f6m","year":"2021","unstructured":"Hagstr\u00f6m H, Adams LA, Allen AM, et al. Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. Hepatology. 2021;74(1):474\u201382. https:\/\/doi.org\/10.1002\/hep.31726.","journal-title":"Hepatology"},{"issue":"7","key":"1558_CR24","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/pds.2148","volume":"20","author":"V Lo Re III","year":"2011","unstructured":"Lo Re III V, Lim JK, Goetz MB, et al. Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf. 2011;20(7):689\u201399. https:\/\/doi.org\/10.1002\/pds.2148.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1558_CR25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"1558_CR26","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/gerona\/gly232","volume":"74","author":"AR Orkaby","year":"2019","unstructured":"Orkaby AR, Nussbaum L, Ho YL, et al. The burden of frailty among U.S. veterans and its association with mortality, 2002\u20132012. J Gerontol A Biol Sci Med Sci. 2019;74(8):1257\u201364. https:\/\/doi.org\/10.1093\/gerona\/gly232.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1558_CR27","unstructured":"Semaglutide Injection Criteria for Use July 2022 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives. Available at: https:\/\/www.va.gov\/formularyadvisor\/DOC_PDF\/CFU_Semaglutide_OZEMPIC_Jul22a.pdf. Accessed 22 Dec 2023."},{"issue":"4","key":"1558_CR28","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/1475-6773.00165","volume":"38","author":"S Schneeweiss","year":"2003","unstructured":"Schneeweiss S, Wang PS, Avorn J, Glynn RJ. Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res. 2003;38(4):1103\u201320. https:\/\/doi.org\/10.1111\/1475-6773.00165.","journal-title":"Health Serv Res"},{"issue":"6","key":"1558_CR29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382. https:\/\/doi.org\/10.1093\/aje\/kwq433.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"1558_CR30","first-page":"358","volume":"2","author":"S Becker","year":"2002","unstructured":"Becker S, Ichino A. Estimation of average treatment effects based on propensity scores. Stand Genomic Sci. 2002;2(4):358\u201377.","journal-title":"Stand Genomic Sci"},{"key":"1558_CR31","unstructured":"Leuven E, Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. 2003. available at: http:\/\/ideas.repec.org\/c\/boc\/bocode\/s432001.html. version 4.0.5 ed. 2003."},{"issue":"25","key":"1558_CR32","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107. https:\/\/doi.org\/10.1002\/sim.3697.","journal-title":"Stat Med"},{"issue":"1","key":"1558_CR33","doi-asserted-by":"publisher","first-page":"10623","DOI":"10.1038\/s41467-024-54009-3","volume":"15","author":"S Zhang","year":"2024","unstructured":"Zhang S, Sidra F, Alvarez CA, Kinaan M, Lingvay I, Mansi IA. Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease. Nat Commun. 2024;15(1):10623. https:\/\/doi.org\/10.1038\/s41467-024-54009-3.","journal-title":"Nat Commun"},{"key":"1558_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.711723","volume":"9","author":"WH Hsu","year":"2021","unstructured":"Hsu WH, Sue SP, Liang HL, et al. Dipeptidyl peptidase 4 inhibitors decrease the risk of hepatocellular carcinoma in patients with chronic hepatitis c infection and type 2 diabetes mellitus: a Nationwide Study in Taiwan. Front Public Health. 2021;9: 711723. https:\/\/doi.org\/10.3389\/fpubh.2021.711723.","journal-title":"Front Public Health"},{"key":"1558_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041148","author":"TI Chen","year":"2023","unstructured":"Chen TI, Lee FJ, Hsu WL, Chen YC, Chen M. Association of dipeptidyl peptidase-4 inhibitors use with reduced risk of hepatocellular carcinoma in type 2 diabetes patients with chronic HBV infection. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15041148.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1558_CR36","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41598-020-57935-6","volume":"10","author":"M Kawakubo","year":"2020","unstructured":"Kawakubo M, Tanaka M, Ochi K, et al. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects. Sci Rep. 2020;10(1):983. https:\/\/doi.org\/10.1038\/s41598-020-57935-6.","journal-title":"Sci Rep"},{"issue":"7","key":"1558_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"JH Lee","year":"2010","unstructured":"Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503\u20138. https:\/\/doi.org\/10.1016\/j.dld.2009.08.002.","journal-title":"Dig Liver Dis"},{"issue":"5","key":"1558_CR38","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/s0895-4356(01)00510-8","volume":"55","author":"R Bender","year":"2002","unstructured":"Bender R, Blettner M. Calculating the \u201cnumber needed to be exposed\u201d with adjustment for confounding variables in epidemiological studies. J Clin Epidemiol. 2002;55(5):525\u201330. https:\/\/doi.org\/10.1016\/s0895-4356(01)00510-8.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1558_CR39","doi-asserted-by":"publisher","first-page":"102696","DOI":"10.1016\/j.dsx.2022.102696","volume":"17","author":"SG Albert","year":"2023","unstructured":"Albert SG, Wood EM, Ahir V. Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes? Diabetes Metab Syndr. 2023;17(1):102696. https:\/\/doi.org\/10.1016\/j.dsx.2022.102696.","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"1558_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40620-023-01858-8","volume":"37","author":"M Brockmeyer","year":"2024","unstructured":"Brockmeyer M, Parco C, Vargas KG, et al. Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data. J Nephrol. 2024;37(2):309\u201321. https:\/\/doi.org\/10.1007\/s40620-023-01858-8.","journal-title":"J Nephrol"},{"issue":"10","key":"1558_CR41","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00592-022-01917-9","volume":"59","author":"O Kuss","year":"2022","unstructured":"Kuss O, Akbulut C, Schlesinger S, et al. Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials of new antidiabetic drugs: a meta-analysis of digitalized individual patient data. Acta Diabetol. 2022;59(10):1349\u201359. https:\/\/doi.org\/10.1007\/s00592-022-01917-9.","journal-title":"Acta Diabetol"},{"issue":"2","key":"1558_CR42","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc22-1148","volume":"46","author":"J Bezin","year":"2023","unstructured":"Bezin J, Gouverneur A, P\u00e9nichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46(2):384\u201390. https:\/\/doi.org\/10.2337\/dc22-1148.","journal-title":"Diabetes Care"},{"issue":"1","key":"1558_CR43","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12902-024-01775-2","volume":"24","author":"M Shabil","year":"2024","unstructured":"Shabil M, Khatib MN, Ballal S, et al. Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis. BMC Endocr Disord. 2024;24(1):246. https:\/\/doi.org\/10.1186\/s12902-024-01775-2.","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"1558_CR44","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1053\/j.gastro.2024.04.029","volume":"167","author":"L Wang","year":"2024","unstructured":"Wang L, Berger NA, Kaelber DC, Xu R. Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes. Gastroenterology. 2024;167(4):689\u2013703. https:\/\/doi.org\/10.1053\/j.gastro.2024.04.029.","journal-title":"Gastroenterology"},{"issue":"12","key":"1558_CR45","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","volume":"48","author":"G Xu","year":"1999","unstructured":"Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48(12):2270\u20136. https:\/\/doi.org\/10.2337\/diabetes.48.12.2270.","journal-title":"Diabetes"},{"key":"1558_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.925377","volume":"13","author":"Z Yang","year":"2022","unstructured":"Yang Z, Lv Y, Yu M, et al. GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS. Front Pharmacol. 2022;13: 925377. https:\/\/doi.org\/10.3389\/fphar.2022.925377.","journal-title":"Front Pharmacol"},{"key":"1558_CR47","doi-asserted-by":"publisher","unstructured":"Arvanitakis K, Koufakis T, Kotsa K, Germanidis G. How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma. Cancers (Basel). Sep 24 2022;14(19) https:\/\/doi.org\/10.3390\/cancers14194651","DOI":"10.3390\/cancers14194651"},{"issue":"2","key":"1558_CR48","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1097\/MLR.0b013e3182a30373","volume":"54","author":"Y Sada","year":"2016","unstructured":"Sada Y, Hou J, Richardson P, El-Serag H, Davila J. Validation of case finding algorithms for hepatocellular cancer from administrative data and electronic health records using natural language processing. Med Care. 2016;54(2):e9-14. https:\/\/doi.org\/10.1097\/MLR.0b013e3182a30373.","journal-title":"Med Care"},{"issue":"5","key":"1558_CR49","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1007\/s10620-017-4503-4","volume":"62","author":"R Omino","year":"2017","unstructured":"Omino R, Mittal S, Kramer JR, Chayanupatkul M, Richardson P, Kanwal F. The validity of HCC diagnosis codes in chronic hepatitis B patients in the veterans health administration. Digestive Dis Sci. 2017;62(5):1180\u20135. https:\/\/doi.org\/10.1007\/s10620-017-4503-4.","journal-title":"Digestive Dis Sci"},{"key":"1558_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092191","author":"E Kawakita","year":"2021","unstructured":"Kawakita E, Koya D, Kanasaki K. CD26\/DPP-4: type 2 diabetes drug target with potential influence on cancer biology. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13092191.","journal-title":"Cancers (Basel)."},{"issue":"7","key":"1558_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134305","volume":"10","author":"A Beckenkamp","year":"2015","unstructured":"Beckenkamp A, Willig JB, Santana DB, et al. Differential expression and enzymatic activity of DPPIV\/CD26 affects migration ability of cervical carcinoma cells. PLoS ONE. 2015;10(7): e0134305. https:\/\/doi.org\/10.1371\/journal.pone.0134305.","journal-title":"PLoS ONE"},{"issue":"334","key":"1558_CR52","doi-asserted-by":"publisher","first-page":"334ra51","DOI":"10.1126\/scitranslmed.aad6095","volume":"8","author":"H Wang","year":"2016","unstructured":"Wang H, Liu X, Long M, et al. NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Sci Transl Med. 2016;8(334):334ra51. https:\/\/doi.org\/10.1126\/scitranslmed.aad6095.","journal-title":"Sci Transl Med."},{"issue":"1","key":"1558_CR53","doi-asserted-by":"publisher","first-page":"784","DOI":"10.18632\/aging.102656","volume":"12","author":"Y Gu","year":"2020","unstructured":"Gu Y, Li X, Bi Y, et al. CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma. Aging (Albany NY). 2020;12(1):784\u2013807. https:\/\/doi.org\/10.18632\/aging.102656.","journal-title":"Aging (Albany NY)."},{"issue":"2","key":"1558_CR54","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/dom.12582","volume":"18","author":"LA Leiter","year":"2016","unstructured":"Leiter LA, Teoh H, Mosenzon O, et al. Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial. Diabetes Obes Metab. 2016;18(2):186\u201390. https:\/\/doi.org\/10.1111\/dom.12582.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1558_CR55","doi-asserted-by":"publisher","first-page":"8273","DOI":"10.1038\/s41598-017-07921-2","volume":"7","author":"M Zhao","year":"2017","unstructured":"Zhao M, Chen J, Yuan Y, et al. Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. Sci Rep. 2017;7(1):8273. https:\/\/doi.org\/10.1038\/s41598-017-07921-2.","journal-title":"Sci Rep"},{"issue":"1","key":"1558_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000728","volume":"7","author":"C Sanbao","year":"2019","unstructured":"Sanbao C, Shuqing Y, Zhirong Y, et al. Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks. BMJ Open Diabetes Res Care. 2019;7(1): e000728. https:\/\/doi.org\/10.1136\/bmjdrc-2019-000728.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"6","key":"1558_CR57","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00592-020-01479-8","volume":"57","author":"I Dicembrini","year":"2020","unstructured":"Dicembrini I, Nreu B, Montereggi C, Mannucci E, Monami M. Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. Acta Diabetol. 2020;57(6):689\u201396. https:\/\/doi.org\/10.1007\/s00592-020-01479-8.","journal-title":"Acta Diabetol"},{"issue":"4","key":"1558_CR58","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.jdiacomp.2017.01.012","volume":"31","author":"W Rathmann","year":"2017","unstructured":"Rathmann W, Kostev K. Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer. J Diabetes Complications. 2017;31(4):687\u201392. https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.01.012.","journal-title":"J Diabetes Complications"},{"key":"1558_CR59","doi-asserted-by":"publisher","first-page":"7427","DOI":"10.2147\/cmar.S215107","volume":"11","author":"YJ Choi","year":"2019","unstructured":"Choi YJ, Kim DJ, Shin S. Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus. Cancer Manag Res. 2019;11:7427\u201338. https:\/\/doi.org\/10.2147\/cmar.S215107.","journal-title":"Cancer Manag Res."},{"issue":"10","key":"1558_CR60","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1681\/ASN.2007020199","volume":"18","author":"LA Stevens","year":"2007","unstructured":"Stevens LA, Coresh J, Feldman HI, et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol. 2007;18(10):2749\u201357. https:\/\/doi.org\/10.1681\/ASN.2007020199.","journal-title":"J Am Soc Nephrol"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01558-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01558-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01558-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:24:10Z","timestamp":1758893050000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01558-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1558"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01558-1","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"6 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This material is the result of work supported with resources and the use of facilities at the Orlando Veterans Affairs (VA) Healthcare System (Orlando, Florida). This research was supported, in whole or in part, by HCA Healthcare and\/or an HCA Healthcare affiliated entity.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of Sponsor"}},{"value":"The authors declared no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The Orlando VA Institutional Review Board approved the study (IRB approval number: 1680940-6).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval Statement"}},{"value":"The Orlando VA institutional review board waived the requirement for informed consent because only preexisting deidentified data were analyzed.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate\/Consent for publication\u00a0"}},{"value":"Data are stored in the VA Informatics and Computing Infrastructure (VINCI), the operational platform for health services research at the Veterans Healthcare Administration (VHA). The VINCI acts as a data steward for the VHA Data Systems. The data in VINCI cannot be copied, transferred, or printed. Access to data by other researchers is possible following the VINCI protocols, ascribed to the VINCI Central website: .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Codes used in the study are provided in Supplementary Material.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The study concept and design: JT, IM, MB, VK; Acquisition of data and statistical analysis: IM; Interpretation of data: JT, IM, MB, VK; manuscript initial draft: JT, MB; critical revision of the manuscript for important intellectual content: IM, JT, MB, VK; study supervision: IM, MB. All authors have read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors Contributions"}}]}}